RLT
Radioligand therapy prostate-specific membrane antigen
Advertisement
Dr. Ulaner highlights 2 new clinical trials for prostate cancer staging and treatment at Hoag: MIRROR and 177Lu-PNT2002.
The open-label VISON study randomly assigned patients to receive either 177Lu-PSMA-617 plus SoC or SoC alone.
A total of 488 patients received an average of 2 cycles of 225Ac-PSMA RLT between January 2016 and May 2023.
The study analyzed VISION-eligible patients with mCRPC who were classified as TheraP-eligible or ineligible.
The study is the first large-scale report of patients in the United States treated with 177Lu-PSMA-617.
Dr. Kishan discusses new research presented at the 2024 PSMA Conference.
The first annual PSMA Conference focused on updates in the field of PSMA-based treatments.
Dr. Oliver Sartor presented his high-level “provocateur” thoughts on the optimal time to give PSMA RLT.
PSA levels were decreased by half in 46.9% of patients, and a decline in CTC count occurred 59.1% of patients.
ASCO has provided a rapid update on its guideline recommendations for 177Lutetium-PSMA-617 in mCRPC.
Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.
Dr. Sartor explains in detail the design and methodology, specific findings, nuances, and implications of the PSMAfore trial.
New research sheds light on the safety of (177Lu)–PSMA-617 for patients with mCRPC and poor bone marrow reserve.
The panel shares insights on future advancements in the field.
The panel discussed the "innovative design" of the phase 2 ENZA-p study presented at ESMO 2023.
The panel discusses treatment-related adverse events, including hematologic toxicities, xerostomia, and more.
The panel discuss patient interest in receiving radioligand therapy in the context of cost and access challenges.
The panel discusses results of the phase 3 PSMAfore study presented at ESMO 2023.
The panel talks "pearls of wisdom" with radioligand therapy.
The panel discusses recommended frequency of scans for patients receiving radioligand therapy, PSA response, and more.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.